DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) announced the acceptance and oral presentation details of two sets of data at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021, which will be held virtually from September 9-10, 2021.
The Company states that a copy of the presentation slides will be made available on the Zynerba corporate website following each presentation at http://zynerba.com/publications/. Additional meeting information can be found on the SSBP website at https://ssbp.org.uk/.
Oral Presentation Details
Title: Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study (BRIGHT [ZYN2-CL-030])
Session: Session 1
Date: September 9, 2021
Time: 5:15 a.m. ET
Title: A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]
Session: Session 4
Date: September 10, 2021
Time: 2:15 p.m. ET
Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.
Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.